Axon Enterprise (AXON) - Company Research

Last Updated: 18 August 2026

Axon Enterprise sells an integrated public-safety ecosystem: TASER energy weapons, body-worn cameras, drones and counter-drone hardware, and an increasingly dominant cloud software layer covering evidence management, real-time operations, AI report drafting and, since February 2026, 911 call handling. Its fiscal year ends on 31 December, and the most recent reported quarter is Q2 2026, ended 30 June 2026 and reported after the close on 5 August 2026. Q3 2026 has not been reported. This report is built entirely from Axon's SEC filings, shareholder letters and SEC XBRL company facts. Every figure below comes from a primary filing; there are no analyst ratings or price targets anywhere in it.

1. Company Snapshot

Field	Value
Ticker / exchange	AXON, Nasdaq Global Select Market. Constituent of the S and P 500 since 4 May 2023
Headquarters	Scottsdale, Arizona, United States
Fiscal year end	31 December
CEO / Leadership	Patrick W. "Rick" Smith, founder and Chief Executive Officer. Brittany Bagley, Chief Operating Officer and Chief Financial Officer. Joshua M. Isner, President
Employees	More than 5,100 full-time employees plus more than 1,200 temporary staff as of 31 December 2025, per the FY2025 Form 10-K. Full-time headcount grew approximately 24 per cent during 2025, though $28.7m of severance was booked in Q4 2025
Revenue (FY2025)	$2,779.5m, up 33.5 per cent on FY2024
Revenue (trailing twelve months to 30 Jun 2026)	$3,219.1m
GAAP net income (FY2025)	$124.7m
Adjusted EBITDA (FY2025)	$710.2m, 25.5 per cent of revenue
Annual recurring revenue	$1,639m at 30 June 2026, up 38.5 per cent year on year
Future contracted bookings	$15.1bn at 30 June 2026, up 41 per cent year on year
Market capitalisation	Approximately $49.1bn at $604.32 per share (18 August 2026)
Shares outstanding	81,237,415 as of 31 July 2026 (Q2 2026 Form 10-Q cover page)
Reportable segments	Two: Connected Devices and Software and Services
Dividend	None. Axon has never declared or paid a cash dividend and states it does not intend to

You can follow the price action on our Live Charts page and check upcoming scheduled events on the Economic Calendar.

2. Bull and Bear Case

Bull Case

• Four consecutive years above 30 per cent growth, and guidance raised twice this year: revenue grew 37.1 per cent, 31.5 per cent, 33.4 per cent and 33.5 per cent in FY2022 through FY2025, and Q2 2026 revenue rose 35.3 per cent to $904.4m. Full-year 2026 guidance has been raised twice, from 27 to 30 per cent in February, to 30 to 32 per cent in May, to 32 to 34 per cent on 5 August 2026.
• Recurring revenue is outgrowing the hardware: annual recurring revenue reached $1,639m at 30 June 2026, up 38.5 per cent and faster than total revenue, with net revenue retention of 126 per cent. Software-only gross margin continues to exceed 80 per cent.
• A contracted backlog worth roughly 4.7 times trailing revenue: future contracted bookings stood at $15.1bn at 30 June 2026, up 41 per cent year on year. Management expects to fulfil 20 to 25 per cent over the next twelve months and the remainder generally over the following ten years, which gives unusual visibility for a company growing this fast.
• The AI tier is the fastest-adopting product in the company's history: AI Era Plan product revenue, comprising the plan plus standalone Draft One and Axon Assistant, grew more than 700 per cent year on year in Q1 2026 and near 700 per cent again in Q2. Draft One customers report 50 to 80 per cent reductions in report-writing time. This is an incremental per-seat step-up on agencies already running Evidence.com, with almost no incremental hardware.
• Adjacent markets bought and integrated: the Prepared acquisition (closed 1 October 2025) and Carbyne (closed 18 February 2026, approximately $551.7m net cash) take Axon into 911 call handling under the new Axon 911 line, while Dedrone grew approximately 300 per cent year on year and drove Platform Solutions up 122.6 per cent in Q2 2026.

Bear Case

• The valuation is the dominant variable: at $604.32 the shares trade on roughly 252 times trailing GAAP earnings, roughly 90 times trailing non-GAAP earnings and roughly 15 times trailing sales. The stock fell from a $791.62 closing high on 18 August 2025 to $345.94 on 10 April 2026, a 56 per cent drawdown, on no company-specific bad news. That is the de-rating risk in plain sight.
• Margin guidance has not moved despite two revenue raises: management held full-year 2026 adjusted EBITDA margin at 25.5 per cent at every raise, citing rising component costs, particularly memory, and ramp costs on Dedrone, Axon Body Mini and Axon 911. Q2's 26.8 per cent margin was flattered by $47m of one-off global tariff refunds that will not repeat in Q3. The shares fell 14.3 per cent the day after the Q2 print on exactly this point.
• Free cash flow has gone backwards while revenue compounds: FY2025 free cash flow was $75.1m, down 77 per cent from $329.5m in FY2024, and first-half 2026 free cash flow was negative $55.6m. Growth is being funded through working capital, with inventory at $486.6m against $341.8m at year end and current contract assets at $750.9m against $582.6m.
• Stock-based compensation is enormous relative to profit: FY2026 stock-based compensation is guided at $590m to $620m, roughly 16 to 17 per cent of guided revenue and more than two-thirds of guided adjusted EBITDA. Diluted shares have risen from 66.2m in FY2021 to 82.5m in Q2 2026, and Axon is still issuing equity through an at-the-market programme with approximately 1.0m shares remaining at 30 June 2026.
• Concentration in politically-exposed public budgets: 82 per cent of Q2 2026 revenue came from the United States, overwhelmingly from state, local and federal public-safety agencies funded by discretionary municipal and grant budgets.

3. Business Segments

Axon reports two segments. The legacy names Software and Sensors and Axon Cloud and Services are no longer used. Percentages below are of Q2 2026 total revenue of $904.389m, with the FY2025 position given alongside.

Segment	% of revenue	What it is
Connected Devices	56.0 per cent in Q2 2026 ($506.553m); 56.7 per cent in FY2025 ($1,576.864m)	All hardware. Comprises TASER handles, cartridges and related warranties; Personal Sensors, meaning body cameras, accessories and signal sidearm; and Platform Solutions, meaning fleet in-car video, interview room, fixed cameras, drones and counter-drone equipment and VR training hardware. Grew 34.6 per cent year on year in Q2 2026 at a 53.4 per cent adjusted gross margin
Software and Services	44.0 per cent in Q2 2026 ($397.836m); 43.3 per cent in FY2025 ($1,202.672m)	Axon Evidence cloud storage and evidence management, Axon Records, Axon Fusus real-time operations, Axon Respond, Axon Air, Draft One, Axon Assistant, Axon Vision, Axon Guardian, and Axon 911 call handling via Carbyne and Prepared. Grew 36.2 per cent year on year in Q2 2026 at a 75.1 per cent adjusted gross margin, with software-only margin above 80 per cent
Product-category detail within Connected Devices, Q2 2026	TASER 28.9 per cent ($261.321m, up 20.9 per cent); Personal Sensors 10.5 per cent ($95.392m, up 2.8 per cent); Platform Solutions 16.6 per cent ($149.840m, up 122.6 per cent)	Platform Solutions is the growth engine inside hardware, driven by Dedrone counter-drone and drone-as-first-responder deployments. Personal Sensors has flattened as body-camera penetration matures in core US agencies

By geography, Q2 2026 revenue was $742.307m from the United States, 82 per cent of the total, and $162.082m from other countries.

4. Business Model and Moat

How it makes money. The original model was classic razor and razorblade: sell the TASER handle, then annuitise on cartridges and batteries. That business is still substantial, at $913.9m or 32.9 per cent of FY2025 revenue. But the strategic shift has been to bundle hardware into a multi-year subscription so the device becomes an entitlement inside a software contract rather than a capital sale. Axon prices in tiered per-officer, per-month bundles rather than by SKU, with the premium tier now the AI Era Plan. The evidence the shift is working is that annual recurring revenue is growing faster than total revenue and future contracted bookings are running at roughly 4.7 times trailing revenue.

Where the moat comes from. Once an agency standardises on Evidence.com, its chain-of-custody, retention and disclosure workflows are built around it, and years of video evidence sit inside it. Switching means migrating evidence with legal defensibility intact, retraining every officer, and re-procuring hardware. That is why net revenue retention runs at 126 per cent and why the AI upsell converts so quickly: the agency is already on the platform, and the AI tier is an incremental per-seat step-up rather than a new procurement. The CJIS-compliant environment Axon has built around its AI products is itself a barrier, since general-purpose AI vendors cannot easily meet criminal-justice data handling requirements.

The land-and-expand motion in numbers. Axon does not depend on single mega-contracts. Its model is many mid-size multi-year agency deals: Springfield, Missouri at $5.3m for 285 body cameras in July 2026, Evanston, Illinois at $5.8m in December 2025, a proposed five-year $27m contract with Denver Police in December 2025, and a body-worn camera rollout across UK fire services in early 2026 that extends the addressable market beyond core policing. Each of those becomes a base for the AI Era Plan upsell.

What it costs to run. The model is expensive in equity. FY2026 stock-based compensation is guided at $590m to $620m, driven largely by the eXponential Stock Plan and the 2024 CEO Performance Award, which vest in tranches against joint revenue-or-EBITDA, stock-price and service conditions. This is why GAAP operating income is close to breakeven while adjusted EBITDA runs at over 25 per cent of revenue, and it is the single most important reconciling item for anyone valuing the business.

5. Financial Health

All figures below are taken from Axon's Forms 10-K and 10-Q, its quarterly shareholder letters, and SEC XBRL company facts for CIK 0001069183. Note that FY2023 figures were revised upward in the FY2024 Form 10-K, with net income restated from $174.227m to $175.783m and diluted EPS from $2.31 to $2.33; the revised figures are used here.

Fiscal Year	Revenue ($m)	YoY %	GAAP EPS	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021 (ended 31 Dec 2021)	865.6	n/a	$(0.91)	$2.35	Nil	Nil
FY2022 (ended 31 Dec 2022)	1,187.1	+37.1%	$2.03	$2.19	Nil	$674.0m
FY2023 (ended 31 Dec 2023)	1,560.7	+31.5%	$2.33	$4.14	Nil	$677.1m
FY2024 (ended 31 Dec 2024)†	2,082.5	+33.4%	$4.80	$5.94	Nil	$0m
FY2025 (ended 31 Dec 2025)	2,779.5	+33.5%	$1.51	$6.85	Nil	$1,730.2m

† The FY2024 non-current long-term debt figure is genuinely $0m rather than missing. The $690.0m of 0.50 per cent convertible senior notes due 2027, issued in December 2022, were reclassified in full to current liabilities at 31 December 2024 at a carrying amount of $680.3m as they approached conversion. Those notes were then fully extinguished by 11 February 2026. The FY2025 figure of $1,730.2m is the carrying amount of $1,000.0m of 6.125 per cent senior notes due 2030 and $750.0m of 6.250 per cent senior notes due 2033, both issued in March 2025. At 30 June 2026 the carrying amount was $1,731.8m with no current portion.

‡ Axon reports both non-GAAP diluted earnings per share and adjusted EBITDA in every quarterly shareholder letter. The Adjusted EPS column above is the company's own non-GAAP diluted EPS. The gap between GAAP and non-GAAP is dominated by stock-based compensation. FY2025 in particular shows GAAP EPS of $1.51 against non-GAAP EPS of $6.85, and FY2024's GAAP EPS of $4.80 was inflated by a large one-off tax benefit rather than by operations. Adjusted EBITDA over the same five years ran $178.1m, $232.3m, $329.3m, $521.4m and $710.2m, at margins of 20.6, 19.5, 21.1, 25.0 and 25.5 per cent.

Quarter / Half	Revenue	Adjusted EPS	GAAP EPS
Q2 2026 (ended 30 Jun 2026)	$904.4m	$1.88	$0.36
Q1 2026 (ended 31 Mar 2026)	$807.3m	$1.61	$2.05
Q4 2025 (ended 31 Dec 2025)	$796.7m	$2.15	$0.03
Q3 2025 (ended 30 Sep 2025)	$710.6m	$1.17	$(0.03)
Q2 2025 (ended 30 Jun 2025)	$668.5m	$2.18	$0.44
Q1 2025 (ended 31 Mar 2025)	$603.6m	$1.47	$1.08
FY2025 total (ended 31 Dec 2025)	$2,779.5m	$6.85	$1.51

Two quarterly figures need context. Q1 2026 GAAP EPS of $2.05 includes a $189.0m other-income gain, largely the fair-value step-up on Axon's pre-existing 10.7 per cent stake in Carbyne plus strategic-investment marks; it is non-operating and should not be annualised. Q2 2026 GAAP net income of $29.4m was below Q2 2025's $36.1m purely for tax reasons, since the prior-year quarter carried a $75.0m tax benefit. On a pre-tax basis Q2 2026 improved from a loss of $38.9m to income of $32.7m, and operating income improved by $47.8m year on year to $46.8m. Quarterly EPS does not sum exactly to the full-year figure because of share-count weighting.

Cash flow and balance sheet. FY2025 operating cash flow was $211.3m against capital expenditure of $136.3m, giving free cash flow of $75.1m. On a trailing twelve-month basis to 30 June 2026, operating cash flow was $265.8m and capital expenditure $132.6m, giving free cash flow of $133.2m. Depreciation and amortisation was $83.2m in FY2025 and $109.4m on a trailing twelve-month basis. At 30 June 2026 Axon held $597.7m of cash and equivalents plus $75.7m of short-term investments against $1,731.8m of fixed-rate senior notes with no maturities before 2030, leaving net debt of approximately $1.1bn. Goodwill rose from $1,370.2m to $1,898.8m in six months on the Carbyne acquisition.

6. Valuation Metrics

Raw metrics, August 2026. Not opinions on whether the stock is cheap or expensive.

Priced at $604.32 per share on 18 August 2026. The last completed regular session close was $612.83 on 14 August 2026. Trailing twelve-month figures are the sum of Q3 2025, Q4 2025, Q1 2026 and Q2 2026.

Metric	Value
Market cap	Approximately $49.1bn ($604.32 x 81,237,415 shares outstanding per the Q2 2026 Form 10-Q cover page)
Enterprise value	Approximately $50.2bn (market cap $49.1bn + total debt $1,731.8m - cash and equivalents $597.7m - short-term investments $75.7m, all per the 30 June 2026 balance sheet). Net debt is approximately $1.1bn
Trailing P/E (GAAP)	Approximately 252x on trailing twelve-month GAAP diluted EPS of $2.40. On trailing twelve-month non-GAAP diluted EPS of $6.69 the same price is approximately 90x. The gap is almost entirely stock-based compensation, guided at $590m to $620m for FY2026
P/E (forward)	Approximately 57.2x on a consensus forward EPS estimate of $10.56 on a non-GAAP basis. Axon issues no EPS guidance at all; it guides revenue growth and adjusted EBITDA margin only, and explicitly declines to reconcile projected net income to projected adjusted EBITDA
P/S (TTM)	Approximately 15.3x (market cap $49.1bn / trailing twelve-month revenue $3,219.1m)
EV/EBITDA (TTM)	Approximately 61x on Axon's own trailing twelve-month adjusted EBITDA of $827.0m. On GAAP EBITDA the multiple is approximately 377x and is not meaningful: GAAP EBITDA of only $133.2m is trailing twelve-month operating income of $23.8m plus depreciation and amortisation of $109.4m, and GAAP operating income is held near breakeven by stock-based compensation of roughly $600m a year. The adjusted figure is the one that reconciles to how the business is managed and to the company's own 2028 target of a 28 per cent adjusted EBITDA margin
P/FCF	Approximately 369x (market cap $49.1bn / free cash flow $133.2m; free cash flow = trailing twelve-month operating cash flow $265.8m - capital expenditure $132.6m per the cash flow statements). Free cash flow is currently suppressed by inventory and contract-asset build funding 33 per cent-plus revenue growth, and first-half 2026 free cash flow was negative $55.6m
52-week high	$794.29 intraday. The highest closing price in the trailing 52 weeks was $791.62 on 18 August 2025
52-week low	$339.01 intraday. The lowest closing price in the trailing 52 weeks was $345.94 on 10 April 2026
Short interest (% of float)	4.39 per cent of shares outstanding, or approximately 4.60 per cent of the 77,424,943-share free float. 3,563,990 shares short at the 31 July 2026 settlement date per the Nasdaq file. A narrower float basis gives 5.20 per cent. Short interest is up roughly 40 per cent year to date but has eased from a June peak of 4,074,449 shares
Days to cover	5.10 on the Nasdaq calculation using 699,220 average daily volume at the 31 July 2026 settlement date. A wider volume window gives 3.93
Dividend yield	Nil. Axon has never paid a dividend and states it does not intend to
Price/book	Approximately 13.4x on book value per share of $45.23

7. What Are They Building

The AI Era Plan and Draft One. Axon's premium subscription tier packages Draft One, which drafts police reports from body-camera audio transcripts, together with Axon Assistant and the newer AI products. Uptake has been the standout number of 2026: AI Era Plan product revenue, comprising the plan plus standalone Draft One and Axon Assistant, grew more than 700 per cent year on year in Q1 2026 and near 700 per cent again in Q2. Agencies report report-writing time reductions of 50 to 80 per cent, with Fort Collins, Colorado citing 67 per cent. Because these agencies are already running Evidence.com, the AI tier is a per-seat upsell rather than a new procurement.

Three new AI products launched at Axon Week 2026. At the Nashville event on 7 to 10 April 2026 Axon introduced Axon Vision, which applies AI analysis to live camera feeds for threat detection; Axon Guardian, which detects escalation on body cameras and can automatically call for assistance through Axon Fusus, with a sentinel mode on fleet cameras; and the cloud-based Axon 911 platform uniting call-taking, video and reporting. Axon Assistant was also expanded across devices inside a CJIS-compliant environment.

Axon 911, built by acquisition. The 911 call-handling business is new. Prepared closed on 1 October 2025 and Carbyne closed on 18 February 2026 for approximately $551.7m net of cash acquired, against a $625m headline value announced on 4 November 2025. Axon already held 10.7 per cent of Carbyne, and the step-up produced a $38.0m non-taxable gain in Q1 2026 along with $523.3m of goodwill and $108.2m of intangibles. Carbyne's purchase price allocation is still open, with the measurement period running to Q1 2027.

Drones and counter-drone. Platform Solutions grew 122.6 per cent year on year in Q2 2026, with Dedrone alone up approximately 300 per cent. This line covers drone-as-first-responder deployments and counter-drone equipment, and it is currently the fastest-growing hardware category by a wide margin. Its scaling is partly gated by US airspace rules on beyond-visual-line-of-sight flight, where the FAA's Part 108 rulemaking remains in progress; Axon has not published a date it relies on.

The 2028 financial targets. Introduced on 24 February 2026, management is targeting approximately $6bn of annual revenue, an adjusted EBITDA margin of approximately 28 per cent, adjusted free cash flow conversion of 60 per cent of adjusted EBITDA, and annual stock-based-compensation dilution below 2.5 per cent. The last of those is an acknowledgement that the current dilution rate is higher.

Compare notes on the AI adoption curve with other members in the ChartsView Forum.

8. Peer Comparison

Market capitalisations were re-checked live on 18 August 2026. Metrics are each from the named company's own results release or SEC filing.

Peer	Market cap (Aug 2026)	Key 2025 metric
Palantir Technologies (PLTR)	Approximately $415bn	FY2025 revenue of $4,475.4m; Q2 2026 revenue of $1,935.5m for the quarter ended 30 June 2026. Overlaps with Axon in government and public-safety software rather than hardware
Motorola Solutions (MSI)	Approximately $75.6bn	FY2025 revenue of $11,682m; Q2 2026 revenue of $3,133m for the quarter ended 4 July 2026. The closest direct competitor across command centre software, video security and land mobile radio
NICE Ltd (NICE)	Approximately $5.72bn	FY2025 revenue of $2,945.4m per its Form 20-F. Competes in public-safety recording and analytics
Cellebrite DI (CLBT)	Approximately $2.62bn	Annual recurring revenue of $508m at 30 June 2026, up 21 per cent but below management's own guidance, with FY2026 ARR guidance cut to $550m to $560m. FY2025 revenue was $475.7m. New Chief Executive Shiv Ramji took office 13 August 2026
Wrap Technologies (WRAP)	Approximately $0.09bn	FY2025 revenue of $4.7m; Q2 2026 revenue of $2.1m. Sub-scale and not a genuine competitive threat at present

Two peers that appear in older comparisons are no longer usable. Verint Systems filed a Form 15-12G on 8 December 2025 and is no longer an SEC reporting company following its take-private; its last public full-year revenue was $909.2m for the year ended 31 January 2025. Digital Ally has been renamed and repositioned as Kustom Entertainment, trading as KUST, with FY2025 revenue of $13.8m, and is no longer a pure body-camera comparable.

9. Insider Activity

Chief Executive Officer Patrick W. "Rick" Smith, the company's founder, sold 70,000 shares for approximately $37.5m between February and August 2026, every tranche under a Rule 10b5-1 plan. Across 51 Form 4 filings since 1 February 2026 there were zero open-market purchases by any insider; every disposition is either a programmed sale or a tax-withholding surrender on vesting. Separately, a company-wide wave of code-A equity settlements landed on 16 August 2026, including 97,015 shares to Rick Smith under the 2024 CEO Performance Award granted on 22 December 2023. These are vesting events, not purchases, and are consistent with Tranche 3 of the eXponential Stock Plan settling now that trailing revenue of $3,219.1m and trailing adjusted EBITDA of $827.0m have cleared the $2,866m and $611m hurdles and the June 2026 service date has passed.

Name	Date	Type	Shares	Price	Value	Plan Type
Patrick W. Smith, Chief Executive Officer	16 Aug 2026	Acquisition, performance award settlement	97,015	Nil	Nil	2024 CEO Performance Award
Joshua M. Isner, President	13 Aug 2026	Tax withholding on vesting	15,704	$615.59	Approximately $9.67m	Withholding, not a market sale
Patrick W. Smith, Chief Executive Officer	07 Aug 2026	Sale	10,000	$548.90	Approximately $5.49m	Rule 10b5-1 plan
Joshua M. Isner, President	05 Aug 2026	Acquisition, award	78,200	Nil	Nil	Equity award
Patrick W. Smith, Chief Executive Officer	07 Jul 2026	Sale	10,000	$643.79	Approximately $6.44m	Rule 10b5-1 plan
Patrick W. Smith, Chief Executive Officer	29 Jun 2026	Sale	10,000	$500.00	$5.00m	Rule 10b5-1 plan
Joshua M. Isner, President	05 Jun 2026	Sale	13,000	$488.45	Approximately $6.35m	10b5-1 plan adopted 17 Dec 2025
Patrick W. Smith, Chief Executive Officer	04 Jun 2026	Sale	20,000	$500.00	$10.00m	Rule 10b5-1 plan
Elizabeth Reid Coughlin, Chief Human Officer	04 Jun 2026	Sale	1,554	$485.00	Approximately $0.75m	No 10b5-1 flag on filing
Brittany Bagley, Chief Operating Officer and Chief Financial Officer	02 Jun 2026	Sale	5,969	$485.00	Approximately $2.90m	No 10b5-1 flag on filing
Isaiah Fields, Chief Legal Officer	22 May 2026	Sale	2,000	$400.00	$0.80m	No 10b5-1 flag on filing
Joshua M. Isner, President	10 Mar 2026	Sale	34,581	$534.39	Approximately $18.48m	No 10b5-1 flag on filing
Patrick W. Smith, Chief Executive Officer	09 Mar 2026	Sale	10,000	$560.24	Approximately $5.60m	Rule 10b5-1 plan
Brittany Bagley, Chief Operating Officer and Chief Financial Officer	02 Mar 2026	Sale	4,266	$552.90	Approximately $2.36m	No 10b5-1 flag on filing
Patrick W. Smith, Chief Executive Officer	25 Feb 2026	Sale	10,000	$500.24	Approximately $5.00m	Rule 10b5-1 plan

Chief Operating Officer and Chief Financial Officer Brittany Bagley, Chief Product Officer and Chief Technology Officer Jeffrey C. Kunins, Chief Revenue Officer Cameron Brooks and Chief Accounting Officer Jennifer H. Mak all received code-A award settlements on 16 August 2026 alongside the Chief Executive. Directors received annual restricted stock unit grants of 611 shares each on 29 May 2026, and the two new directors appointed on 8 July 2026, Vivek Mohindra and Eiso Kant, each received 600 shares.

10. Key Risks

• Valuation and multiple compression: at roughly 252 times trailing GAAP earnings, 90 times trailing non-GAAP earnings and 15 times trailing sales, the shares carry no valuation support. The 56 per cent drawdown from $791.62 on 18 August 2025 to $345.94 on 10 April 2026 happened on no company-specific bad news, which is the clearest available evidence of how the stock behaves when high-multiple growth de-rates.
• Margin compression from mix and component costs: management held the FY2026 adjusted EBITDA margin at 25.5 per cent even while raising revenue guidance twice, citing rising memory and component costs and the ramp of lower-margin Dedrone, Axon Body Mini and Axon 911. Software and Services adjusted gross margin fell 380 basis points year on year to 75.1 per cent on professional-services mix, and Q2's headline 26.8 per cent margin was flattered by $47m of one-off tariff refunds.
• Negative and lumpy free cash flow: FY2025 free cash flow fell 77 per cent to $75.1m from $329.5m, and first-half 2026 free cash flow was negative $55.6m. Inventory rose to $486.6m from $341.8m and current contract assets to $750.9m from $582.6m. Growth is being funded from working capital, and only 20 to 25 per cent of the $15.1bn backlog converts within twelve months.
• Shareholder dilution and stock-based compensation intensity: FY2026 stock-based compensation of $590m to $620m is roughly 16 to 17 per cent of guided revenue and more than two-thirds of guided adjusted EBITDA. Diluted shares rose from 66.2m in FY2021 to 82.5m in Q2 2026, and the at-the-market equity programme is still live with approximately 1.0m shares remaining at 30 June 2026.
• AI and civil-liberties regulation on Draft One: the ACLU and EFF have publicly criticised Draft One for not retaining or marking the AI-generated first draft, arguments that could compromise reports as evidence. Utah and then California, through SB 524 signed in October 2025, now require disclosure and audit trails for AI-assisted police reports, and more states are legislating. Because AI Era Plan revenue is the fastest-growing and highest-margin line, an adverse regulatory turn lands directly on it.
• Concentration in law-enforcement budgets: 82 per cent of Q2 2026 revenue came from the United States, overwhelmingly from state, local and federal public-safety agencies funded by discretionary municipal and grant budgets that are politically exposed and cyclically vulnerable.
• Patent litigation aimed at the newest growth lines: Airspace Systems is suing Axon and Dedrone in the Eastern District of Virginia over drone technology, seeking injunctive relief and treble damages, with the case stayed pending USPTO validity decisions expected in October 2026. Separately, CentralSquare Technologies is suing Carbyne in the Western District of Texas over 911 technology with trial set for May 2027. Both target the drone and 911 businesses driving current growth.
• Residual antitrust and product-liability exposure: the FTC dismissed its administrative complaint over the Vievu acquisition in October 2023 without consent decree or condition, but a purported antitrust class action brought by three municipalities remains pending in the District of New Jersey, based largely on the FTC's unproven allegations. Separately, as a weapons manufacturer Axon is a defendant in two wrongful-death or personal-injury suits involving TASER devices; it self-insures the first $5.0m per claim and states no judgment or settlement has ever exceeded that amount.
• Acquisition integration and goodwill: goodwill rose from $1,370.2m to $1,898.8m in six months and strategic investments from $416.8m to $853.8m. Axon paid approximately $1.18bn in cash for Prepared and Carbyne within five months, and Carbyne's purchase accounting remains open, explicitly including pre-acquisition legal contingencies.

For completeness, none of the above is a liquidity, solvency or going-concern risk. Axon holds approximately $685m of cash and short-term investments against $1.8bn of fixed-rate senior notes with no maturities before 2030, generates positive trailing adjusted EBITDA of $827.0m, and has a $15.1bn contracted backlog.

11. Recent Developments

• 16 Dec 2025 — Convertible note exchanges clean up the capital structure. Axon exchanged $196.854m principal of its 0.50 per cent 2027 convertible notes for $196.86m cash plus 526,802 shares, ahead of calling the balance.
• 18 Dec 2025 — Notice of redemption issued for all remaining 2027 convertible notes. Axon called the balance for a 10 February 2026 redemption date.
• 31 Dec 2025 — Workforce reduction booked in Q4 2025. Axon recorded $28.7m of non-recurring severance in selling, general and administrative expense and $1.1m in research and development, approximately $31.8m in total. The Form 10-K does not disclose how many roles were cut.
• 11 Feb 2026 — Convertible notes fully extinguished. $0.84m was redeemed for cash and $80.27m of conversions were settled with approximately $80.3m cash and 211,870 shares, with 41,139 shares received back from hedge counterparties. No convertible notes remain outstanding.
• 17 Feb 2026 — Nathan Cummings Foundation sues over exclusion of a shareholder proposal. The foundation sought expedited injunctive relief to force a political-spending-transparency proposal into the 2026 proxy. A judge ordered the parties toward a compromise and the matter was subsequently settled.
• 18 Feb 2026 — Carbyne acquisition closes, taking Axon into 911 call handling. Axon bought the remaining 89.3 per cent of Carbyne for approximately $551.7m net cash, booking a $38.0m non-taxable gain on its prior 10.7 per cent stake plus $523.3m of goodwill. Together with Prepared, this anchors the new Axon 911 line.
• 24 Feb 2026 — Q4 and FY2025 results beat and the shares rose 17.6 per cent the next session. Q4 revenue of $797m up 39 per cent and adjusted EPS of $2.15 against roughly $1.60 expected. FY2025 revenue of $2.78bn up 33 per cent, a fourth straight year above 30 per cent, with FY2025 bookings of $7.4bn up 46 per cent. Initial FY2026 guidance of 27 to 30 per cent growth and new 2028 targets of approximately $6bn revenue and a 28 per cent adjusted EBITDA margin were introduced.
• 06 Apr 2026 — Second director departure announced. Matthew McBrady notified the board he would not stand for re-election, following Julie Anne Cullivan on 5 March 2026. Both filings state the decisions were not the result of any disagreement with the company.
• 10 Apr 2026 — Shares hit a 52-week closing low of $345.94. Roughly 56 per cent below the August 2025 high, on general high-multiple-growth de-rating and margin concerns rather than any company-specific disclosure.
• 10 Apr 2026 — Three new AI products launched at Axon Week 2026 in Nashville. Axon Vision for AI analysis of live camera feeds, Axon Guardian for escalation detection on body cameras with automatic assistance calls through Axon Fusus, and the cloud-based Axon 911 platform. Axon Assistant was expanded across devices in a CJIS-compliant environment.
• 06 May 2026 — Q1 2026 results and the first guidance raise. Revenue of $807m up 34 per cent, AI Era Plan product revenue up more than 700 per cent year on year, Platform Solutions up 95 per cent and Dedrone alone up 300 per cent. FY2026 revenue growth guidance lifted from 27 to 30 per cent, to 30 to 32 per cent.
• 08 Jul 2026 — Two new independent directors appointed. Vivek Mohindra joined the Audit and Compensation Committees and Eiso Kant joined as a non-voting observer on the M and A and Capital Structure Committee, each with initial terms to the 2027 annual meeting and $260,000 initial restricted stock unit awards.
• 30 Jul 2026 — Continued press criticism of Draft One's evidentiary value. Commentators argued Axon's own evidence shows Draft One makes reports faster but not demonstrably better, echoing the EFF's charge that the product does not retain or mark the AI-generated first draft.
• 05 Aug 2026 — Q2 2026 results beat and guidance was raised again, but the shares fell 14.3 per cent the next day. Revenue of $904.4m up 35 per cent beat roughly $876.5m consensus and adjusted EPS of $1.88 beat $1.83, with FY2026 growth guidance raised to 32 to 34 per cent. But the adjusted EBITDA margin guide was held at 25.5 per cent, with management flagging higher component costs especially in memory, no further tariff-refund benefit in Q3, and ramp costs on Dedrone, Axon Body Mini and Axon 911. The stock fell from a $609.49 close on 5 August to $522.46 on 6 August, then recovered to $636.31 by 11 August.
• 16 Aug 2026 — Company-wide performance-award settlement. Rick Smith received 97,015 shares under the 2024 CEO Performance Award, alongside code-A settlements to Isner, Bagley, Kunins, Brooks, Fields, Coughlin and Mak, consistent with Tranche 3 of the eXponential Stock Plan vesting.

No published short-seller report on Axon was found in this period.

12. Key Dates

• Expected Nov 2026 — Q3 2026 results. Not yet announced as of 18 August 2026. Q3 2025 was reported on 4 November 2025 and Q3 2024 on 7 November 2024; Axon typically announces the date around two weeks in advance
• Expected Oct 2026 — USPTO decision on Axon and Dedrone's validity challenges to all three patents asserted by Airspace Systems. The infringement suit in the Eastern District of Virginia is stayed pending this decision
• 31 Dec 2026 — minimum service date for Tranche 4 of the eXponential Stock Plan and 2024 CEO Performance Award, which also requires trailing revenue of $3,583m or adjusted EBITDA of $801m and a $483.20 share price. Trailing revenue was already $3,219.1m and trailing adjusted EBITDA $827.0m at 30 June 2026
• Expected Feb 2027 — Q4 and full-year 2026 results, plus initial FY2027 guidance. FY2025 was reported on 24 February 2026 and FY2024 on 25 February 2025
• Expected Mar 2027 — completion of the Carbyne purchase price allocation as the measurement period closes in Q1 2027
• Expected May 2027 — trial in CentralSquare Technologies LLC versus Carbyne in the Western District of Texas, a 911-technology patent suit in which Carbyne has counterclaimed
• Expected Jun 2027 — 2027 annual meeting of stockholders. The 2026 annual meeting was held on 1 June 2026, and the new directors' initial terms expire at the 2027 meeting
• TBC — FAA Part 108 final rule on beyond-visual-line-of-sight drone operations, which gates the scaling of the drone-as-first-responder business. The rule remained at proposal stage in the sources available and no firm date has been confirmed
• TBC — Axon Week 2027. Axon Week 2026 was held 7 to 10 April 2026 in Nashville, but no 2027 date has been published

Full-year 2026 guidance, as issued on 5 August 2026, is for revenue growth of 32 to 34 per cent and an adjusted EBITDA margin of 25.5 per cent. Applied to FY2025 revenue of $2,779.5m, that implies approximately $3.67bn to $3.72bn of FY2026 revenue and approximately $935m to $950m of adjusted EBITDA.

---

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.